IMCR Immunocore Holdings plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1671927 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.1%
TTM net income YoY-9.9%
TTM EPS YoY-10.3%
Revenue 3-yr CAGR25.9%
Net income 3-yr CAGR—
Margins
Gross margin98.9%
Operating margin-6.8%
Net margin-7.5%
FCF margin-4.2%
EBITDA margin-5.9%
Returns
ROE-7.9%
ROA-2.9%
ROIC (approx.)—
Asset turnover0.38x
Leverage & solvency
Liabilities / assets62.8%
Debt / equity0.00x
Current ratio4.62x
Interest coverage-2.37x
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · USD | FY20222022-12-31 · GBP | FY20212021-12-31 · GBP |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $400.02M | $310.20M | $249.43M | 143.74M | 26.52M |
| Cost of revenue | $5.09M | $2.73M | $1.04M | 454,000 | 0 |
| Gross profit | $394.93M | $307.47M | $248.39M | 143.28M | 26.52M |
| R&D expense | $274.87M | $222.15M | $163.54M | 89.17M | 73.23M |
| SG&A expense | $165.41M | $155.78M | $144.50M | 93.72M | 88.40M |
| Operating income | -$45.35M | -$70.46M | -$59.65M | -39.61M | -135.16M |
| Interest expense | $12.17M | $18.84M | $5.15M | 7.69M | 5.81M |
| Pretax income | -$19.10M | -$52.94M | -$60.89M | -44.15M | -140.93M |
| Income tax | $16.41M | -$1.85M | -$5.60M | -2.92M | -9.40M |
| Net income | -$35.51M | -$51.09M | -$55.29M | -$52.54MUSD | -$180.03MUSD |
| EBITDA | -$42.25M | -$66.26M | -$55.55M | — | — |
| EPS (basic) | -0.71 | -1.02 | -1.13 | -0.90 | -3.10 |
| EPS (diluted) | -0.71 | -1.02 | -1.13 | -0.90 | -3.10 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00USD | — |
| Weighted avg. shares (diluted) | 50.35M | 49.99M | 48.89M | 45.71M | 42.49M |
| Balance sheet | |||||
| Cash & equivalents | $467.71M | $455.73M | $442.63M | 332.54M | 237.89M |
| Short-term investments | $396.44M | $364.64M | $0 | — | — |
| Receivables | — | $63.01M | $52.09M | 46.71M | 15.21M |
| Inventory | $6.74M | $5.45M | $4.50M | 943,000 | 0 |
| Current assets | $996.74M | $929.86M | $528.82M | 391.88M | 262.73M |
| PP&E, net | $11.46M | $10.09M | $9.21M | 6.47M | 8.94M |
| Total assets | $1.07B | $1.01B | $597.00M | 435.52M | 301.77M |
| Current liabilities | $246.70M | $212.18M | $139.02M | 83.09M | 61.18M |
| Short-term debt | — | — | — | 0 | — |
| Long-term debt | — | — | — | 39.50M | 37.23M |
| Total debt | — | — | — | 39.50M | 37.23M |
| Total liabilities | $686.24M | $648.79M | $228.16M | 156.76M | 130.23M |
| Shareholders' equity | $381.03M | $360.72M | $368.84M | $338.90MUSD | $233.71MUSD |
| Net debt | — | — | — | -293.04M | -200.66M |
| Shares outstanding | 50.69M | 50.06M | 49.73M | 48.09M | 212,238 |
| Cash flow statement | |||||
| Operating cash flow | -$10.71M | $26.06M | $2.94M | -25.89M | -96.11M |
| Capital expenditure | $4.34M | $5.17M | $5.42M | 1.79M | 1.01M |
| Free cash flow | -$15.05M | $20.89M | -$2.48M | -27.68M | -97.12M |
| Investing cash flow | -$16.34M | -$355.13M | -$5.42M | 193,000 | -367,000 |
| Financing cash flow | $12.37M | $343.88M | $34.35M | 114.45M | 204.63M |
| Depreciation & amortization | $3.10M | $4.20M | $4.10M | $5.30MUSD | $7.60MUSD |
| Stock-based compensation | $37.70M | $34.19M | $32.47M | 27.05M | 35.86M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.